MedPath

Time-restricted Eating for Postpartum Weight Loss

Not Applicable
Recruiting
Conditions
Postpartum Weight Retention
Overweight and Obesity
Registration Number
NCT06491537
Lead Sponsor
University of Alabama at Birmingham
Brief Summary

This study is being done to assess the feasibility and acceptability of a time-restricted eating intervention among postpartum women with overweight/obesity.

Detailed Description

Existing postpartum weight retention (PPWR) interventions have had limited success. Timing-based interventions, such as early time-restricted eating (eTRE), show significant improvements in cardiometabolic endpoints in non-postpartum cohorts. The purpose of the Time4Mom study is to conduct a pilot randomized trial of a postpartum-adapted eTRE intervention to test feasibility and acceptability of the eTRE intervention and trial protocol. We will also compare changes in clinical outcomes of interest and patient-reported outcomes between eTRE (intervention) and control groups.

This 2-arm trial will randomize 60 postpartum women to either Control or eTRE for 12 weeks (n=30/group).

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • 18 years of age or older
  • Experienced a healthy singleton pregnancy
  • 6-16 weeks postpartum at enrollment
  • Body mass index ≥25 at enrollment
  • Willing to consent
Exclusion Criteria
  • Self-reported major health condition (such as renal disease, cancer, or Type 1 or Type 2 diabetes)
  • Current treatment for severe psychiatric disorder (such as schizophrenia)
  • Self-reported diagnosis of anorexia or bulimia
  • Current use of medication expected to significantly impact body weight
  • Current substance abuse
  • Participation in another dietary and/or weight management intervention postpartum
  • Performing overnight shiftwork >1x/week
  • Regularly fasting ≥14 hr/day or completing twelve or more 24-hr fasts within the past year
  • Unable to understand and communicate in English

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Study Participation RateBaseline (6-16 weeks postpartum)

Percentage of eligible subjects who agreed to participate out of those who were screened.

Oral Glucose Tolerance Test (OGTT)Baseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Indices of glucose tolerance and insulin action will be assessed via a 2-hr OGTT. Participants will consume a 75-g glucose load within 5 minutes, which will be timed to begin at each participant's habitual breakfast time. Fasting blood samples will be collected at 15-, 30-, 60-, 90-, and 120-minutes relative to glucose consumption.

Energy IntakeBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Dietary intake will be collected at each assessment by 3 self-administered 24-hr recalls on 3 non-consecutive days (2 weekdays, 1 weekend day) using the Automatic Self-Administered 24-hour Dietary Assessment Tool (ASA24), an online platform developed and hosted by the National Cancer Institute. Total energy intake and kcals from each macronutrient will be derived from 24-hr recalls.

Participant RetentionBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

The proportion of enrolled participants who complete follow-up.

Change in Visceral FatBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Bioelectrical impedance analysis (BIA) (seca® mBCA 514) will be used to assess visceral adipose tissue.

Participant Adherence to InterventionCollected daily from intervention start (6-16 weeks postpartum) to follow-up (18-28 weeks postpartum)

Adherence to eating window based on responses to daily electronic REDCap surveys that record start and stop time of the eating window.

eTRE Intervention SatisfactionBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Participant satisfaction with the eating schedule will be assessed using a 5-point Likert scale. Long-term eating schedule preferences will be assessed by asking intervention participants at follow-up whether they plan to: (a) continue following the assigned eTRE schedule; (b) follow a modified eTRE schedule \[and specifying what modifications they plan to make\]; or (c) stop eTRE and return to prior meal timing habits.

Qualitative data on eTRE intervention satisfaction will be collected at follow-up. These one-on-one interviews will be conducted in-person or remotely via videoconferencing. Topics explored will include participants' typical day during the intervention, experiences with eTRE, adherence barriers/facilitators, intervention satisfaction, and suggested improvements.

Change in Body WeightBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Body weight measured at baseline and follow-up will be used to calculate weight change.

Change in Subjective AppetiteBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Subjective ratings of appetite (hunger and satiety) over the past week will be collected at baseline and follow-up using visual analogue scales scored from 0 (less hunger/less satiety) to 100 (more feelings of hunger/more feelings of satiety) based on the response along a 100-mm line.

Self-Reported FatigueBaseline (6-16 weeks postpartum), follow-up (18-28 weeks postpartum)

Fatigue will be assessed using the NIH's validated 8-item Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 8a to assess fatigue over the past 7 days. The PROMIS Fatigue SF 8a is scored on a T-score metric with a mean of 50 and standard deviation of 10. The T-score metric is referenced to the US general population with respect to race/ethnicity, age, education, and sex (e.g., T-score of 40 would be one SD below the US general population). A higher PROMIS T-score represents more of the concept being measured (higher score indicates more fatigue).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Camille S Worthington, PhD
Contact
205-975-7274
cschneid@uab.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.